--- title: "Fortress Biotech (FBIO) news: merger" url: "https://aibio.space/companies/fortress-biotech/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "FBIO merger news: Fortress Biotech to receive about $28.0 million as Checkpoint merger with Sun Pharma closes. Fortress Biotech, Inc." --- FBIO Fortress Biotech, Inc. NASDAQ · United States # Fortress Biotech (FBIO) news FBIO merger news Financings · 2026-02-23 ## [Fortress subsidiary Cyprium agrees to sell priority review voucher for $205 million](https://aibio.space/news/fortress-subsidiary-cyprium-agrees-sell-priority-review-voucher-205/) Cyprium, a majority-owned Fortress Biotech subsidiary, agreed on February 22, 2026 to sell a priority review voucher for $205 million in cash at closing. Fortress also amended its Oaktree credit agreement, with about $29.5 million outstanding. ## Latest Fortress Biotech news 1. 2025-06-05 Mergers [Fortress Biotech to receive about $28.0 million as Checkpoint merger with Sun Pharma closes](https://aibio.space/news/fortress-biotech-receive-about-28-0-million-checkpoint-sale-sun-pharma/) Checkpoint Therapeutics became a wholly owned Sun Pharma subsidiary on May 30, 2025. Fortress may also get up to $4.8 million through CVRs and a 2.5% royalty on certain net sales. 2. 2025-06-05 Mergers [Fortress Biotech to receive about $28.0 million as Checkpoint sale to Sun Pharma closes](https://aibio.space/news/fortress-biotech-receive-about-28-0-million-checkpoint-sale-sun-pharma/) Fortress Biotech says it will receive about $28.0 million in cash from the sale of Checkpoint Therapeutics to Sun Pharma, with up to $4.8 million more if a milestone is met. The gain on deconsolidation is an accounting figure, and pro forma cash is lower than reported. 3. 2025-03-10 Mergers [Fortress Biotech's Checkpoint unit agrees to Sun Pharma deal at $4.10 a share plus CVR](https://aibio.space/news/fortress-biotechs-checkpoint-unit-agrees-sun-pharma-deal-4-10-share/) Checkpoint Therapeutics, the majority-controlled unit of Fortress Biotech, agreed to be bought by Sun Pharma for $4.10 in cash per share plus a contingent value right of up to $0.70. Fortress has agreed to vote in favor and will receive a 2.5% royalty. 4. 2025-02-07 Financings [Mustang Bio prices $8 million offering at $3.01 with two series of warrants](https://aibio.space/news/mustang-bio-prices-8-million-offering-3-01-two-series-warrants/) The warrants can be exercised only after stockholders approve. The offering follows a 1-for-50 reverse stock split on January 15, 2025. ## Fortress Biotech at a glance - **Ticker**: FBIO - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $196.6 million ### Related companies - [Veradermics](https://aibio.space/companies/veradermics/) NYSE: MANE - [Fulcrum Therapeutics](https://aibio.space/companies/fulcrum-therapeutics/) NASDAQ: FULC - [AbbVie](https://aibio.space/companies/abbvie/) NYSE: ABBV - [aTyr Pharma](https://aibio.space/companies/atyr-pharma/) NASDAQ: ATYR - [Vertex Pharmaceuticals](https://aibio.space/companies/vertex-pharmaceuticals/) NASDAQ: VRTX - [Amylyx Pharmaceuticals](https://aibio.space/companies/amylyx-pharmaceuticals/) NASDAQ: AMLX - [Assembly Biosciences](https://aibio.space/companies/assembly-biosciences/) NASDAQ: ASMB - [Biofrontera](https://aibio.space/companies/biofrontera-bfri/) NASDAQ: BFRI ### Also on NASDAQ - [Trevi Therapeutics](https://aibio.space/companies/trevi-therapeutics/) TRVI - [Oric Pharmaceuticals](https://aibio.space/companies/oric-pharmaceuticals/) ORIC - [Incyte](https://aibio.space/companies/incyte/) INCY - [Mirum Pharmaceuticals](https://aibio.space/companies/mirum-pharmaceuticals/) MIRM - [Xenetic Biosciences](https://aibio.space/companies/xenetic-biosciences/) XBIO - [IRulya Therapeutics](https://aibio.space/companies/irulya-therapeutics/) IRLA ## What Fortress Biotech does Fortress Biotech is a biopharmaceutical company focused on acquiring and advancing assets through product revenue, equity holding, and dividend and royalty revenue streams. After acquiring or licensing the intellectual property behind a product candidate, Fortress helps its subsidiaries and partner companies pursue development and commercialization, which may include joint ventures, partnerships, out-licensings and financings. Named institutional and corporate partners include City of Hope National Medical Center, Dana-Farber Cancer Institute, AstraZeneca, Dr. Reddy's Laboratories and Sun Pharmaceutical Industries. Its partner company Journey Medical markets branded dermatology products in the United States, including Emrosi, a 40mg minocycline capsule for rosacea approved in November 2024. The FDA approved ZYCUBO (copper histidinate) on January 13, 2026 for pediatric patients with Menkes disease. Fortress is eligible for a 2.5% royalty on net sales of UNLOXCYT (cosibelimab-ipdl), after the May 2025 acquisition of its former subsidiary Checkpoint by Sun Pharma. In February 2026, Avenue Therapeutics obtained an exclusive license from Duke University for ATX-04 (clenbuterol) for lysosomal storage diseases. | Product or program | What it is | Stage | |---|---|---| | Emrosi | Oral minocycline hydrochloride extended-release capsule for rosacea in adults, marketed by Journey | Approved in the US; launched March 2025 | | ZYCUBO (copper histidinate) | Treatment of pediatric patients with Menkes disease | Approved in the US, January 13, 2026 | | Qbrexza | Medicated cloth towelette for primary axillary hyperhidrosis, marketed by Journey | Approved in the US | | UNLOXCYT (cosibelimab-ipdl) | Product from former subsidiary Checkpoint; Fortress receives a 2.5% royalty | | | ATX-04 (clenbuterol) | Lysosomal storage disease candidate licensed from Duke University by Avenue | License agreement entered February 18, 2026 | Summarised from the company's [10-K filed Mar 31, 2026](https://www.sec.gov/Archives/edgar/data/1429260/000110465926037874/fbio-20251231x10k.htm). ## Fortress Biotech annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$63.3 million](https://www.sec.gov/Archives/edgar/data/1429260/000110465926037874/) | [$57.7 million](https://www.sec.gov/Archives/edgar/data/1429260/000110465926037874/) | | Net income (loss) | [$6.8 million](https://www.sec.gov/Archives/edgar/data/1429260/000110465926037874/) | [-$46.0 million](https://www.sec.gov/Archives/edgar/data/1429260/000110465926037874/) | | Cash from operations | [-$65.8 million](https://www.sec.gov/Archives/edgar/data/1429260/000110465926037874/) | [-$80.2 million](https://www.sec.gov/Archives/edgar/data/1429260/000110465926037874/) | | Cash and equivalents | [$79.4 million](https://www.sec.gov/Archives/edgar/data/1429260/000110465926095964/) | [$57.3 million](https://www.sec.gov/Archives/edgar/data/1429260/000110465926037874/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $196.6 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Fortress Biotech Is Fortress Biotech involved in a merger or acquisition? Our latest story on this, dated Jun 5, 2025: "Fortress Biotech to receive about $28.0 million as Checkpoint merger with Sun Pharma closes". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/fortress-biotech-receive-about-28-0-million-checkpoint-sale-sun-pharma/). What is the ticker symbol of Fortress Biotech? Fortress Biotech, Inc. trades under the ticker FBIO on NASDAQ. Where is Fortress Biotech listed? Fortress Biotech, Inc. is listed on NASDAQ. Our directory also records these other listings: NASDAQ:FBIOP. What is the SEC CIK of Fortress Biotech? The SEC Central Index Key (CIK) for Fortress Biotech, Inc. is 1429260. Its filings are on SEC EDGAR. How many shares does Fortress Biotech have outstanding? 82,474,127 shares as of 2020-05-07, per the cover page of its 10-Q filed 2020-05-11. Which country or territory is Fortress Biotech listed under? Our directory records Fortress Biotech, Inc. under United States. What does Fortress Biotech do? Our directory classifies Fortress Biotech, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Fortress Biotech? The ISIN recorded for Fortress Biotech, Inc. is US34960Q3074. Does aibio.space cover Fortress Biotech? aibio.space lists Fortress Biotech, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Fortress Biotech incorporated? SEC records list its state or country of incorporation as DE. What does Fortress Biotech develop? Fortress Biotech is a biopharmaceutical company focused on acquiring and advancing assets through product revenue, equity holding, and dividend and royalty revenue streams. After acquiring or licensing the intellectual property behind a product candidate, Fortress helps its subsidiaries and partner companies pursue development and commercialization, which may include joint ventures, partnerships, out-licensings and financings. What is Emrosi from Fortress Biotech? Emrosi: Oral minocycline hydrochloride extended-release capsule for rosacea in adults, marketed by Journey Stage: Approved in the US; launched March 2025. What is ZYCUBO (copper histidinate) from Fortress Biotech? ZYCUBO (copper histidinate): Treatment of pediatric patients with Menkes disease Stage: Approved in the US, January 13, 2026. What was Fortress Biotech's revenue last year? $63.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Fortress Biotech profitable? Fortress Biotech, Inc. reported net income of $6.8 million for the fiscal year ended Dec 31, 2025, and used $65.8 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Fortress Biotech Members talk about Fortress Biotech (FBIO). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Fortress Biotech, newest first. Each line links the filing it comes from. 1. 2026-03-30 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1429260/000110465926036818/fbio-20260330xex99.htm) 2. 2026-02-23 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1429260/000110465926018371/fbio-20260222xex99.htm) 3. 2025-12-15 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02). [Source](https://www.sec.gov/Archives/edgar/data/1429260/000110465925121187/fbio-20251212x8k.htm) 4. 2025-06-05 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1429260/000155837025008433/fbio-20250530xex99.htm) 5. 2025-03-10 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1429260/000155837025002541/fbio-20250309x8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:FBIO on TradingView](https://www.tradingview.com/symbols/NASDAQ-FBIO/). ## SEC filings and registration - **SEC name**: Fortress Biotech, Inc. - **CIK**: 1429260 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: FBIO (Nasdaq), FBIOP (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 1111 KANE CONCOURSE, BAY HARBOR ISLANDS, FL, 33154 - **Phone**: 781-652-4500 - **Shares outstanding**: 82,474,127 as of 2020-05-07 (10-Q filed 2020-05-11) - **Former names**: Fortress Biotech, Inc.; CORONADO BIOSCIENCES INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1429260/000110465926112845/fbio-20260930x8k.htm) filed 2026-10-01 - [10-Q](https://www.sec.gov/Archives/edgar/data/1429260/000110465926095964/fbio-20260630x10q.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1429260/000110465926095931/fbio-20260813x8k.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1429260/000110465926076811/fbio-20260617x8k.htm) filed 2026-06-23 - [10-Q](https://www.sec.gov/Archives/edgar/data/1429260/000110465926061233/fbio-20260331x10q.htm) filed 2026-05-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1429260/000110465926061208/fbio-20260514x8k.htm) filed 2026-05-14 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1429260/000110465926050358/fbio-20260617xdef14a.htm) filed 2026-04-28 - [10-K](https://www.sec.gov/Archives/edgar/data/1429260/000110465926037874/fbio-20251231x10k.htm) filed 2026-03-31 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001429260), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Fortress Biotech, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker FBIO, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Fortress Biotech, Inc. - **Ticker**: FBIO - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US34960Q3074 - **Other listed symbols**: NASDAQ:FBIOP - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-FBIO/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/fortress-biotech/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Fortress Biotech (FBIO) news: merger", 2026-10-31, https://aibio.space/companies/fortress-biotech/